[go: up one dir, main page]

MXPA02000437A - Composicion para el tratamiento de trastornos de secrecion externa. - Google Patents

Composicion para el tratamiento de trastornos de secrecion externa.

Info

Publication number
MXPA02000437A
MXPA02000437A MXPA02000437A MXPA02000437A MXPA02000437A MX PA02000437 A MXPA02000437 A MX PA02000437A MX PA02000437 A MXPA02000437 A MX PA02000437A MX PA02000437 A MXPA02000437 A MX PA02000437A MX PA02000437 A MXPA02000437 A MX PA02000437A
Authority
MX
Mexico
Prior art keywords
treatment
composition
secretion disorders
external secretion
dry
Prior art date
Application number
MXPA02000437A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of MXPA02000437A publication Critical patent/MXPA02000437A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composicion para el tratamiento de trastornos de secrecion externa que comprende, como un ingrediente activo, un derivado de acido graso; la composicion de la presente invencion es util para el tratamiento de por lo menos una condicion seleccionada de hipolagrimeo incluyendo trastorno de secrecion de lagrimas basal, sindrome de ojo reseco, hiposalivacion y sindrome de boca reseca.
MXPA02000437A 1999-07-14 2000-07-13 Composicion para el tratamiento de trastornos de secrecion externa. MXPA02000437A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14362799P 1999-07-14 1999-07-14
PCT/JP2000/004696 WO2001005388A2 (en) 1999-07-14 2000-07-13 Use of a fatty derivative for the treatment of external secretiondisorders

Publications (1)

Publication Number Publication Date
MXPA02000437A true MXPA02000437A (es) 2004-05-21

Family

ID=22504885

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02000437A MXPA02000437A (es) 1999-07-14 2000-07-13 Composicion para el tratamiento de trastornos de secrecion externa.

Country Status (25)

Country Link
US (3) US6566398B1 (es)
EP (1) EP1223925B1 (es)
JP (2) JP4167828B2 (es)
KR (1) KR100750553B1 (es)
CN (4) CN101829120B (es)
AR (2) AR029381A1 (es)
AT (1) ATE344027T1 (es)
AU (1) AU779936B2 (es)
BR (1) BRPI0012387B1 (es)
CA (1) CA2377661C (es)
CZ (1) CZ303958B6 (es)
DE (1) DE60031710T2 (es)
DK (1) DK1223925T3 (es)
ES (1) ES2273706T3 (es)
HK (1) HK1048443B (es)
HU (1) HU229318B1 (es)
IL (2) IL147440A0 (es)
MX (1) MXPA02000437A (es)
NO (1) NO323908B1 (es)
PT (1) PT1223925E (es)
RU (1) RU2264816C2 (es)
TR (1) TR200200065T2 (es)
TW (1) TWI225398B (es)
WO (1) WO2001005388A2 (es)
ZA (1) ZA200109726B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
US20030232858A1 (en) * 2002-06-14 2003-12-18 Barker Ronnie C. Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US20040185075A1 (en) 2003-01-31 2004-09-23 Maria Dalko Use of at least one (dihydro)jasmonic acid derivative for treating dry skin
FR2850571B1 (fr) * 2003-01-31 2006-07-07 Oreal Utilisation d'un derive d'acide(dihydro) jasmonique pour le traitement des peaux seches
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CA2541302A1 (en) 2003-10-06 2005-04-14 Ophtecs Corporation Ophthalmic composition for treating tear dysfunction
US7923471B2 (en) 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
WO2006007510A1 (en) * 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
EP1841433B1 (en) * 2005-01-27 2011-11-30 Sucampo AG Composition for treating central nervous system disorders
AR055038A1 (es) * 2005-03-04 2007-08-01 Sucampo Ag Metodo y compuesto para tratar enfermedades vasculares perifericas
US7638142B2 (en) * 2005-10-12 2009-12-29 Vitamin Science, Inc. Therapeutic composition for the treatment of dry eye syndrome
KR20140147142A (ko) 2006-01-24 2014-12-29 가부시키가이샤 아루떼꾸 우에노 바이-사이클릭 화합물을 함유하는 약학적 조성물 및 바이-사이클릭 화합물의 안정화 방법
EP2114411A2 (en) * 2007-02-27 2009-11-11 Sucampo AG Composition and method for protecting mitochondria
US20090053309A1 (en) * 2007-08-24 2009-02-26 Axiomedic Ltd., Gibraltar Adhesive compositions for the treatment of xerostomia
US9161909B2 (en) 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US9597278B2 (en) 2008-11-13 2017-03-21 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en) 2008-11-13 2018-02-06 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US8918181B2 (en) 2010-11-16 2014-12-23 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
BR112014002712A8 (pt) * 2011-08-05 2017-06-20 Sucampo Ag método para tratamento da esquizofrenia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
WO2014172693A2 (en) 2013-04-19 2014-10-23 Oculeve, Inc. Nasal stimulation devices and methods
MX2017005204A (es) 2014-10-22 2017-12-14 Oculeve Inc Dispositivos y métodos de estimulación para tratar el ojo seco.
WO2017192572A1 (en) 2016-05-02 2017-11-09 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
WO2019208435A1 (ja) 2018-04-26 2019-10-31 ライオン株式会社 外分泌促進剤

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
IE49783B1 (en) 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
JPH07103096B2 (ja) * 1987-01-28 1995-11-08 株式会社上野製薬応用研究所 プロスタグランジンｄ類およびそれを含む鎮静・睡眠剤
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
DE3711164A1 (de) 1987-04-02 1988-10-20 Zeiss Carl Fa Steckelementeinrichtung zur halterung von bauteilen in stapeln
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
JPS63277604A (ja) * 1987-05-11 1988-11-15 Showa Denko Kk α−リノレン酸含有化粧料
JPH0692305B2 (ja) * 1987-05-15 1994-11-16 株式会社上野製薬応用研究所 体温上昇剤
ATE82499T1 (de) * 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
SU1673123A1 (ru) * 1987-12-04 1991-08-30 Научно-исследовательский институт морфологии человека АМН СССР Способ лечени болезни и синдрома Шегрена
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
WO1990001323A1 (en) 1988-08-12 1990-02-22 Bernstein Joel E Method and composition for treating and preventing dry skin disorders
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
TW249226B (es) * 1990-04-04 1995-06-11 Aderk Ueno Kk
JPH07100655B2 (ja) * 1990-04-04 1995-11-01 株式会社アールテック・ウエノ 白内障処置剤
CA2041417C (en) * 1990-05-01 2002-05-21 Ryuji Ueno Treatment of pancreatic disease with 15-keto-prostaglandin compounds
JPH07113012B2 (ja) * 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規１５−ケト−プロスタグランジン類
DK0503887T3 (da) * 1991-03-14 1996-09-16 R Tech Ueno Ltd Fremme af sårheling med 15-ketoprostaglandinforbindelser
US5369127A (en) 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
AU2183800A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of dry eye
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
EP1841433B1 (en) * 2005-01-27 2011-11-30 Sucampo AG Composition for treating central nervous system disorders
AR055038A1 (es) * 2005-03-04 2007-08-01 Sucampo Ag Metodo y compuesto para tratar enfermedades vasculares perifericas

Also Published As

Publication number Publication date
NO323908B1 (no) 2007-07-16
PT1223925E (pt) 2007-01-31
DK1223925T3 (da) 2007-03-19
US7396946B2 (en) 2008-07-08
CN100548977C (zh) 2009-10-14
JP5052423B2 (ja) 2012-10-17
KR20020060149A (ko) 2002-07-16
HU229318B1 (hu) 2013-10-28
HUP0202400A2 (hu) 2002-11-28
AR074465A2 (es) 2011-01-19
DE60031710D1 (de) 2006-12-14
ATE344027T1 (de) 2006-11-15
ES2273706T3 (es) 2007-05-16
CN101829120A (zh) 2010-09-15
EP1223925B1 (en) 2006-11-02
IL147440A0 (en) 2002-08-14
CA2377661C (en) 2012-05-08
US20050090556A1 (en) 2005-04-28
BRPI0012387B1 (pt) 2016-11-08
NO20020133L (no) 2002-03-13
CZ303958B6 (cs) 2013-07-17
WO2001005388A3 (en) 2002-05-10
NO20020133D0 (no) 2002-01-11
AU5853300A (en) 2001-02-05
DE60031710T2 (de) 2007-09-06
TWI225398B (en) 2004-12-21
JP2009007360A (ja) 2009-01-15
CN101695495A (zh) 2010-04-21
ZA200109726B (en) 2002-08-30
US6566398B1 (en) 2003-05-20
WO2001005388A2 (en) 2001-01-25
TR200200065T2 (tr) 2002-10-21
JP2003504397A (ja) 2003-02-04
HUP0202400A3 (en) 2005-02-28
AR029381A1 (es) 2003-06-25
CZ2002133A3 (cs) 2002-06-12
JP4167828B2 (ja) 2008-10-22
KR100750553B1 (ko) 2007-08-20
EP1223925A2 (en) 2002-07-24
BR0012387A (pt) 2002-03-26
US20030171438A1 (en) 2003-09-11
AU779936B2 (en) 2005-02-17
CA2377661A1 (en) 2001-01-25
CN1915971A (zh) 2007-02-21
CN101829120B (zh) 2013-09-18
RU2264816C2 (ru) 2005-11-27
HK1048443B (en) 2007-06-08
CN1399548A (zh) 2003-02-26
HK1048443A1 (en) 2003-04-04
IL147440A (en) 2008-11-03

Similar Documents

Publication Publication Date Title
MXPA02000437A (es) Composicion para el tratamiento de trastornos de secrecion externa.
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
MD1315B1 (en) Oxim esters and intermediate compositions, process for preparation thereof, compositions, process for pests control.
MY115339A (en) Compositions containing micronized nebivolol
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2002094210A3 (de) Kosmetische mittel
IL148903A0 (en) Certain alkylene diamine-substituted heterocycles
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
EP2018874A3 (en) Pharmaceutical compositions for the prevention and treatment of central nervous system disorders comprising a nicotinic compound and an acetylcholinesterase inhibitor
EP0795548A4 (en) CHINAZOZINE DERIVATIVES AND THEIR USE
EP1232757A4 (en) MEDICINE FOR DISEASES ASSOCIATED WITH LOSS OF BONE SUBSTANCE
EP0882450A3 (en) Cholesterol-lowering composition comprising coenzyme Q
HK1039745A1 (zh) 用於改善识别的非典型抗精神病药和乙酰胆碱酯酶
AU5446299A (en) Medicinal compositions for treating eye diseases
CA2415354A1 (en) Phospholipid derivatives of valproic acid and mixtures thereof
BR0012696A (pt) Composição oftálmica
TWI256292B (en) Reduction inhibitory agent for active oxygen eliminating activity
NO973652L (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
TW200502222A (en) Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
HK1046404A1 (zh) 用作nmda受体拮抗剂的取代的吡咯烷-2，3，4-三酮-3-肟衍生物
MY129619A (en) A formulation of dihydroartemisinin for the control of the wide spectrum of malaria and a process for preparing the same.

Legal Events

Date Code Title Description
FG Grant or registration